Table 3.
Univariate and multivariate analysis of predictors of LTP after caudate lobe ablation
| Factors | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| P value | HR | 95%CI | P value | ||
| Gender(M/F) | 0.401 | ||||
| Age(≤60/>60y) | 0.811 | ||||
| Tumor type (naive/recurrent) | 0.846 | ||||
| Surgery history of liver (Y/N) | 0.655 | ||||
| Etiology (Hepatitis/others) | 0.821 | ||||
| Liver cirrhosis (Y/N) | 0.499 | ||||
| Antiviral treatment (Y/N) | 0.539 | ||||
| ECOG performance status (0/1) | 0.768 | ||||
| Child-Pugh (A/B) | 0.998 | ||||
| BCLC stage of primary HCC (A/B) | 0.661 | ||||
| AFP (≥400/< 400 μg/L) | 0.432 | ||||
| PLT (≥100/< 100 × 109/L) | 0.530 | ||||
| PT (≤14/> 14 s) | 0.877 | ||||
| ALB (≤35/> 35 g/L) | 0.280 | ||||
| ALT (≤40/> 40 IU/L) | 0.162 | ||||
| TB (≤17.1/> 17.1 mol/L) | 0.616 | ||||
| Tumor number (single /multiple) | 0.336 | ||||
| Location (Paracaval portion/ Caudate process/ Spiegel’s lobe) | 0.466 | ||||
| Tumor size (≤2 cm /> 2 cm) | 0.029 | 3.667 | 1.043–12.889 | 0.043 | |
| Puncture approach (LA/ RA/ combination approach) | 0.921 | ||||
| Treatment strategy | RFA/ EA/ RFA-EA | 0.099 | – | – | – |
| EA/RFA or RFA-EA | 0.223 | ||||
| RFA or EA/RFA-EA | 0.054 | – | – | – | |
| AM (≥ 5 mm / < 5 mm) | 0.336 | ||||
HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, LA left lobe approach, RA right intercostal approach, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA, AM ablative margin